Respiratory Diagnostics Market by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) - Global Forecast to 2029
The global respiratory diagnostics market is projected to reach USD 8.2 billion by 2029 from USD 5.6 billion in 2023, at a CAGR of 6.6% during the forecast period. The growth of the respiratory diagnostics market is propelled by a combination of factors that collectively address the increasing global burden of respiratory diseases. Technological advancements, particularly in diagnostic tools and imaging techniques, have greatly improved the precision and efficiency of respiratory diagnostics, allowing for early detection and more effective management of conditions like COPD, TB, and lung cancer etc. Rising awareness among healthcare professionals and the public about the importance of early diagnosis, coupled with government-led screening programs, has contributed to a higher demand for respiratory diagnostic tests. The emergence of the COVID-19 pandemic has added a new dimension to the market, emphasizing the urgency of rapid and accurate diagnostics for respiratory infections. Changes in regulations, such as new requirements for product approval, labeling, or quality standards, can restrain the market growth.
'Instruments and Devices segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.'
Due to the continuous advancements in diagnostic technologies, including imaging devices, spirometers, and other respiratory diagnostic instruments. Additionally, the increasing prevalence of respiratory diseases worldwide has driven the demand for sophisticated and accurate diagnostic tools, amplifying the significance of this segment. Innovations in point-of-care testing devices and portable diagnostic instruments have further fueled the growth of the Instruments and Devices segment, enabling healthcare professionals to conduct rapid and precise respiratory assessments. Hence, the aforementioned factors are driving the growth of the respiratory diagnostics market.
'The Mechanical tests segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.'
Mechanical tests encompass a range of diagnostic tools, such as spirometers and peak flow meters, which play a significant role in evaluating lung capacity and airflow. The growing prevalence of respiratory disorders, coupled with the need for accurate diagnosis and monitoring, has propelled the demand for mechanical tests. Additionally, advancements in technology have enhanced the efficiency and accuracy of these tests, further driving their widespread adoption. Increasing demand for precise and comprehensive mechanical assessments of respiratory function will drive the growth of the respiratory diagnostics market.
'Asthma segment accounted for the largest share of the global respiratory diagnostics market.'
The rise in environmental pollutants, changing lifestyles, and genetic factors contribute to the growing incidence of asthma, necessitating advanced diagnostic solutions. The Asthma segment encompasses a range of diagnostic modalities, including pulmonary function tests, imaging techniques, and biomarker assessments, providing a comprehensive approach to asthma diagnosis and management. The continuous research and development efforts in this segment, with a focus on personalized medicine, are driving the growth of the respiratory diagnostics market.
“Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market.'
The rise in respiratory diseases, coupled with the growing awareness of the importance of early detection, has led to a surge in diagnostic procedures conducted in these facilities. The Hospitals and Clinics segment encompasses a wide range of diagnostic tools and services, including imaging studies, pulmonary function tests, and molecular diagnostics, providing a comprehensive approach to respiratory health assessment. By the increasing demand for respiratory diagnostic services in healthcare settings, where hospitals and clinics play a central role in disease diagnosis, management, and treatment, position this segment at the forefront of addressing the evolving challenges in respiratory diagnostics.
“North America to Witness Significant Growth From 2023 to 2029.”
Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the respiratory diagnostics market, commanding the largest market share throughout the forecast period. This leadership position is attributed to several factors, including a well-established healthcare infrastructure, high prevalence of respiratory diseases, and robust research and development activities in the region. The sophisticated diagnostic technologies available, coupled with a strong emphasis on early disease detection and management, contribute to the region's dominance. Additionally, increased healthcare spending, a rising geriatric population, and growing awareness about respiratory health further propel market growth.
Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 35%, Tier 2 – 40%, and Tier 3 – 25% • By Designation: C-level – 30%, Director-level – 23%, and Others – 47% • By Region: North America - 35%, Europe – 20%, APAC – 25%, Latin America – 13%, Middle East & Africa – 7%
Some of the prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc. (US), GE HealthCare (US), Bio-Rad Laboratories, Inc. (US), BioMйrieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthcare GmbH (Germany), Cosmed (Italy), Hologic, Inc. (US), Qiagen (Netherlands), Vyaire (US), Visby Medical, Inc (US), Briota Technologies Private Limited (India), Bird Healthcare (Australia), Lцwenstein Medical Technology (Germany), ProAxsis (Northern Ireland), ndd Medical Technologies (US) and Compumedics Limited (Australia).
Research Coverage
This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
'Instruments and Devices segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.'
Due to the continuous advancements in diagnostic technologies, including imaging devices, spirometers, and other respiratory diagnostic instruments. Additionally, the increasing prevalence of respiratory diseases worldwide has driven the demand for sophisticated and accurate diagnostic tools, amplifying the significance of this segment. Innovations in point-of-care testing devices and portable diagnostic instruments have further fueled the growth of the Instruments and Devices segment, enabling healthcare professionals to conduct rapid and precise respiratory assessments. Hence, the aforementioned factors are driving the growth of the respiratory diagnostics market.
'The Mechanical tests segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.'
Mechanical tests encompass a range of diagnostic tools, such as spirometers and peak flow meters, which play a significant role in evaluating lung capacity and airflow. The growing prevalence of respiratory disorders, coupled with the need for accurate diagnosis and monitoring, has propelled the demand for mechanical tests. Additionally, advancements in technology have enhanced the efficiency and accuracy of these tests, further driving their widespread adoption. Increasing demand for precise and comprehensive mechanical assessments of respiratory function will drive the growth of the respiratory diagnostics market.
'Asthma segment accounted for the largest share of the global respiratory diagnostics market.'
The rise in environmental pollutants, changing lifestyles, and genetic factors contribute to the growing incidence of asthma, necessitating advanced diagnostic solutions. The Asthma segment encompasses a range of diagnostic modalities, including pulmonary function tests, imaging techniques, and biomarker assessments, providing a comprehensive approach to asthma diagnosis and management. The continuous research and development efforts in this segment, with a focus on personalized medicine, are driving the growth of the respiratory diagnostics market.
“Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market.'
The rise in respiratory diseases, coupled with the growing awareness of the importance of early detection, has led to a surge in diagnostic procedures conducted in these facilities. The Hospitals and Clinics segment encompasses a wide range of diagnostic tools and services, including imaging studies, pulmonary function tests, and molecular diagnostics, providing a comprehensive approach to respiratory health assessment. By the increasing demand for respiratory diagnostic services in healthcare settings, where hospitals and clinics play a central role in disease diagnosis, management, and treatment, position this segment at the forefront of addressing the evolving challenges in respiratory diagnostics.
“North America to Witness Significant Growth From 2023 to 2029.”
Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the respiratory diagnostics market, commanding the largest market share throughout the forecast period. This leadership position is attributed to several factors, including a well-established healthcare infrastructure, high prevalence of respiratory diseases, and robust research and development activities in the region. The sophisticated diagnostic technologies available, coupled with a strong emphasis on early disease detection and management, contribute to the region's dominance. Additionally, increased healthcare spending, a rising geriatric population, and growing awareness about respiratory health further propel market growth.
Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 35%, Tier 2 – 40%, and Tier 3 – 25% • By Designation: C-level – 30%, Director-level – 23%, and Others – 47% • By Region: North America - 35%, Europe – 20%, APAC – 25%, Latin America – 13%, Middle East & Africa – 7%
Some of the prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc. (US), GE HealthCare (US), Bio-Rad Laboratories, Inc. (US), BioMйrieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthcare GmbH (Germany), Cosmed (Italy), Hologic, Inc. (US), Qiagen (Netherlands), Vyaire (US), Visby Medical, Inc (US), Briota Technologies Private Limited (India), Bird Healthcare (Australia), Lцwenstein Medical Technology (Germany), ProAxsis (Northern Ireland), ndd Medical Technologies (US) and Compumedics Limited (Australia).
Research Coverage
This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
- Analysis of key drivers (rising prevalence of respiratory diseases, Increasing incidence rate of preterm births, growing outbreaks of infectious diseases affecting the respiratory system, growing population with sleep disorders, rising R&D investments for technological advancement of medical devices), restraints (unfavorable reimbursement scenario for respiratory care diagnostics), opportunities (high respiratory diagnostics market growth opportunities in Asia Pacific and Latin America, improving POC diagnostics, growing awareness about the ill effects of untreated sleep apnea), and challenges (low awareness and lack of diagnosis of respiratory diseases) influencing the growth of respiratory diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key industry insights
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V.
FIGURE 8 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022)
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 11 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET
2.8 IMPACT OF RECESSION ON RESPIRATORY DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION)
FIGURE 14 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION)
FIGURE 15 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION)
FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
FIGURE 18 TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET
4.2 GEOGRAPHICAL GROWTH OPPORTUNITIES: RESPIRATORY DIAGNOSTICS MARKET
FIGURE 19 NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022
4.3 REGIONAL MIX: RESPIRATORY DIAGNOSTICS MARKET
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 DEVELOPED VS. EMERGING ECONOMIES: RESPIRATORY DIAGNOSTICS MARKET, 2023 VS. 2029 (USD MILLION)
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of respiratory diseases
5.2.1.1.1 Growth in global geriatric population
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION
5.2.1.1.2 Urbanization and growing pollution levels
FIGURE 24 PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY YEAR)
5.2.1.1.3 Rising prevalence of tobacco smoking
TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS
5.2.1.1.4 Changing lifestyle, obesity, and physical inactivity
5.2.1.2 Increasing rate of preterm births
TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020
FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020
5.2.1.3 Increasing outbreaks of infectious diseases affecting respiratory system
5.2.1.4 Growing population with sleep disorders
5.2.1.5 Rising R&D investments for technologically advanced medical devices
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement policies
5.2.2.2 Availability of low-cost products from local manufacturers
5.2.3 OPPORTUNITIES
5.2.3.1 Increased market growth in Asia Pacific and Latin America
5.2.3.2 Improving POC diagnostics
5.2.3.3 Increasing ill effects of untreated sleep apnea
TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA
5.2.4 CHALLENGES
5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases
5.3 INDUSTRY TRENDS
5.3.1 RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES
5.3.2 FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS
5.3.3 INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
5.5 TARIFF AND REGULATORY ANALYSIS
5.5.1 REGULATORY ANALYSIS
5.5.1.1 North America
5.5.1.1.1 US
TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT
TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.1.2 Canada
TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.2 Europe
TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.3 Asia Pacific
5.5.1.3.1 Japan
TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.3.2 China
TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.3.3 India
5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.1 North America
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.2 Europe
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.3 Rest of the World
TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.6 ECOSYSTEM MARKET MAP
FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET
5.7 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Digitalization of diagnostic tests
5.8.2 ADJACENT TECHNOLOGIES
5.8.2.1 Rapid respiratory diagnostic kits
5.8.3 COMPLEMENTARY TECHNOLOGIES
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS
FIGURE 29 PATENT PUBLICATION TRENDS, 2013 2023
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013 NOVEMBER 2023)
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013 NOVEMBER 2023)
5.10 TRADE ANALYSIS
TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION)
5.11 CASE STUDY ANALYSIS
TABLE 15 MONITORING OF COPD PATIENTS AT HOME
TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES
TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS
5.12 PORTER S FIVE FORCES ANALYSIS
TABLE 18 PORTER S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY CONFERENCES & EVENTS
TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023 2024
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.14.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
5.15 PRICING ANALYSIS
TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD)
5.15.1 AVERAGE SELLING PRICE TREND, BY REGION
5.16 ADJACENT MARKETS
FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET
5.17 UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES
5.18 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
5.18.1 USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE
5.19 REIMBURSEMENT SCENARIO ANALYSIS
TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET
6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE
6.1 INTRODUCTION
TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
6.2 INSTRUMENTS AND DEVICES
6.2.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET
TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021 2029 (USD MILLION)
6.3 ASSAYS AND REAGENTS
6.3.1 RISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET
TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021 2029 (USD MILLION)
6.4 SERVICES AND SOFTWARE
6.4.1 INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET
TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021 2029 (USD MILLION)
7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE
7.1 INTRODUCTION
TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
7.2 MECHANICAL TESTS
TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.2.1 PULMONARY FUNCTION TESTS
TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
7.2.2 SPIROMETRY
7.2.2.1 Spirometry to dominate pulmonary function tests segment during forecast period
TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.2.3 PEAK FLOW TESTS
7.2.3.1 Precise measurements from peak flow tests to help focus on effective treatment plans
TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.2.4 OBSTRUCTIVE SLEEP APNEA TESTS
7.2.4.1 Increased focus on diagnosis of sleep apnea at early stages to drive segment
TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.2.5 OTHER MECHANICAL TESTS
TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3 IMAGING TESTS
TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.3.1 X-RAY
7.3.1.1 Increased investments in advanced radiographic technologies for superior lung imaging to drive segment
TABLE 40 X-RAY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.2 COMPUTED TOMOGRAPHY
7.3.2.1 Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive segment
TABLE 41 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.3 MAGNETIC RESONANCE IMAGING
7.3.3.1 Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment
TABLE 42 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.4 POSITRON EMISSION TOMOGRAPHY
7.3.4.1 Increased focus on effective treatment and management of lung cancer to drive segment
TABLE 43 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.5 OTHER IMAGING TESTS
TABLE 44 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.4 TRADITIONAL DIAGNOSTIC TESTS
TABLE 45 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 46 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.4.1 IMMUNODIAGNOSTICS
7.4.1.1 Increased focus on rapid disease diagnosis to drive segment
TABLE 47 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.4.2 BIOCHEMICAL CHARACTERIZATION
7.4.2.1 Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment
TABLE 48 BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.4.3 MICROSCOPY
7.4.3.1 Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market
TABLE 49 MICROSCOPY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5 MOLECULAR DIAGNOSTIC TESTS
TABLE 50 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 51 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.5.1 PCR
7.5.1.1 Development of portable, real-time PCR machines and assays to drive segment
TABLE 52 PCR MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.2 NUCLEIC ACID AMPLIFICATION
7.5.2.1 Growing focus on automated nucleic acid amplification processes to drive segment
TABLE 53 NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.3 IN SITU HYBRIDIZATION
7.5.3.1 Increased adoption of automated technologies for streamlined respiratory testing to drive segment
TABLE 54 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
7.5.4.1 Rising number of research activities on sequencing-based biomarkers to drive segment
TABLE 55 DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.5 MICROARRAYS
7.5.5.1 Easy and effective detection of genetic signatures across multiple genes to drive segment
TABLE 56 MICROARRAYS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS
TABLE 57 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION
8.1 INTRODUCTION
TABLE 58 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
8.2 TUBERCULOSIS
8.2.1 INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET
TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021 2029 (USD MILLION)
8.3 ASTHMA
8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021 2029 (USD MILLION)
8.4 LUNG CANCER
8.4.1 INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET
TABLE 61 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021 2029 (USD MILLION)
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
8.5.1 INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET
TABLE 62 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021 2029 (USD MILLION)
8.6 OTHER RESPIRATORY DISEASES
TABLE 63 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021 2029 (USD MILLION)
9 RESPIRATORY DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 64 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
TABLE 65 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021 2029 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET
TABLE 66 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021 2029 (USD MILLION)
9.4 OTHER END USERS
TABLE 67 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021 2029 (USD MILLION)
10 RESPIRATORY DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
FIGURE 35 RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT
TABLE 68 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021 2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 70 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 71 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 72 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 73 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 74 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 75 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 76 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 77 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 78 NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate North American respiratory diagnostics market during forecast period
TABLE 79 US: KEY MACROINDICATORS
TABLE 80 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 81 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 82 US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 83 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 84 US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 85 US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 86 US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 87 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 88 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market
TABLE 89 CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020)
TABLE 90 CANADA: KEY MACROINDICATORS
TABLE 91 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 92 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 93 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 94 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 95 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 96 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 97 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 98 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 99 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3 EUROPE
TABLE 100 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 101 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 102 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 103 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 104 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 105 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 106 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 107 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 108 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 109 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing public healthcare expenditure to drive market
TABLE 110 GERMANY: KEY MACROINDICATORS
TABLE 111 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 112 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 113 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 114 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 115 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 116 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 117 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 118 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 119 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing prevalence of COPD and growing geriatric population to drive market
TABLE 120 FRANCE: KEY MACROINDICATORS
TABLE 121 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 122 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 123 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 124 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 125 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 126 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 127 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 128 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 129 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.4 UK
10.3.4.1 Rising number of hospitals and increasing government funding to drive market
TABLE 130 UK: KEY MACROINDICATORS
TABLE 131 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 132 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 133 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 134 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 135 UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 136 UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 137 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 138 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 139 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Unfavorable reforms and reduction in healthcare expenditure by government to limit market
TABLE 140 ITALY: KEY MACROINDICATORS
TABLE 141 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 142 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 143 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 144 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 145 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 146 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 147 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 148 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 149 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Increasing healthcare spending and growing demand for home care services to drive market
TABLE 150 SPAIN: KEY MACROINDICATORS
TABLE 151 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 152 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 153 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 154 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 155 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 156 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 157 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 158 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 159 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 160 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 161 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 162 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 163 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 164 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 165 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 166 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 167 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 168 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 37 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
TABLE 169 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 170 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 171 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 172 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 174 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 177 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 178 ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market
TABLE 179 JAPAN: KEY MACROINDICATORS
TABLE 180 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 181 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 182 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 183 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 184 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 185 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 186 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 187 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 188 JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Modern healthcare systems and improved reimbursement policies to drive market
TABLE 189 CHINA: KEY MACROINDICATORS
TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Large patient population and availability of skilled medical professionals to drive market
TABLE 199 INDIA: KEY MACROINDICATORS
TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Growing prevalence of chronic lung diseases to drive market
TABLE 209 AUSTRALIA: KEY MACROINDICATORS
TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Increasing geriatric population and rising disposable income to drive market 220" "TABLE 219 SOUTH KOREA: KEY MACROINDICATORS
TABLE 220 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 221 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 222 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 223 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 224 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 225 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 226 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 227 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 228 SOUTH KOREA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 229 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 230 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 231 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 232 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5 LATIN AMERICA
TABLE 238 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 239 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 240 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 241 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 242 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 243 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 244 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 245 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 246 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 247 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Favorable healthcare initiatives by government to drive market
TABLE 248 BRAZIL: KEY MACROINDICATORS
TABLE 249 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 250 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 251 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 252 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 253 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 254 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 255 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 256 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 257 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Rising obesity rates and improving medical tourism to drive market
TABLE 258 MEXICO: KEY MACROINDICATORS
TABLE 259 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 260 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 261 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 262 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 263 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 264 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 265 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 266 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 267 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 268 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PATIENT POPULATION AND INCREASING PENETRATION OF PRIVATE HEALTH INSURANCE COMPANIES TO DRIVE MARKET
TABLE 277 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 285 MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY STRATEGIES/RIGHT TO WIN
TABLE 286 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET
11.3 REVENUE SHARE ANALYSIS
FIGURE 38 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2018 2022 (USD MILLION)
FIGURE 39 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2018 2022 (USD MILLION)
11.4 MARKET SHARE ANALYSIS
FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET SHARE FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2022
FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2022
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 42 COMPANY EVALUATION MATRIX, 2022
11.5.5 COMPANY FOOTPRINT
TABLE 287 PRODUCT AND SERVICE FOOTPRINT
TABLE 288 TEST TYPE FOOTPRINT
TABLE 289 END USER FOOTPRINT
TABLE 290 REGIONAL FOOTPRINT
TABLE 291 OVERALL COMPANY FOOTPRINT
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 43 START-UP/SME EVALUATION MATRIX, 2022
11.6.5 COMPETITIVE BENCHMARKING
11.7 COMPETITIVE SCENARIOS AND TRENDS
11.7.1 KEY PRODUCT LAUNCHES
TABLE 292 KEY PRODUCT LAUNCHES, 2021 2023
11.7.2 KEY DEALS
TABLE 293 KEY DEALS, 2021 2023
11.7.3 OTHER KEY DEVELOPMENTS
TABLE 294 OTHER KEY DEVELOPMENTS, 2021 2023
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 KONINKLIJKE PHILIPS N.V.
TABLE 295 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
12.1.2 BECTON, DICKINSON AND COMPANY
TABLE 296 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.3 ABBOTT
TABLE 297 ABBOTT: COMPANY OVERVIEW
FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2022)
12.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 298 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
12.1.5 GE HEALTHCARE
TABLE 299 GE HEALTHCARE: COMPANY OVERVIEW
FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
12.1.6 BIO-RAD LABORATORIES, INC.
TABLE 300 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
12.1.7 BIOMERIEUX
TABLE 301 BIOMERIEUX: COMPANY OVERVIEW
FIGURE 50 BIOMERIEUX: COMPANY SNAPSHOT (2022)
12.1.8 REVVITY, INC.
TABLE 302 REVVITY, INC.: COMPANY OVERVIEW
FIGURE 51 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
12.1.9 SEEGENE INC.
TABLE 303 SEEGENE INC.: COMPANY OVERVIEW
FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2022)
12.1.10 NIHON KOHDEN CORPORATION
TABLE 304 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2022)
12.1.11 VITALOGRAPH
TABLE 305 VITALOGRAPH: COMPANY OVERVIEW
12.1.12 SDI DIAGNOSTICS
TABLE 306 SDI DIAGNOSTICS: COMPANY OVERVIEW
12.1.13 RESMED
TABLE 307 RESMED: COMPANY OVERVIEW
FIGURE 54 RESMED: COMPANY SNAPSHOT (2022)
12.1.14 SIEMENS HEALTHCARE GMBH
TABLE 308 SIEMENS HEALTHCARE GMBH: COMPANY OVERVIEW
FIGURE 55 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022)
12.1.15 COSMED SRL
TABLE 309 COSMED SRL: COMPANY OVERVIEW
12.1.16 HOLOGIC, INC.
TABLE 310 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
12.1.17 QIAGEN
TABLE 311 QIAGEN: COMPANY OVERVIEW
FIGURE 57 QIAGEN: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 VYAIRE MEDICAL, INC.
12.2.2 VISBY MEDICAL, INC.
12.2.3 BRIOTA TECHNOLOGIES PVT. LTD.
12.2.4 BIRD HEALTHCARE
12.2.5 LOWENSTEIN MEDICAL TECHNOLOGY GMBH
12.2.6 PROAXSIS
12.2.7 NDD MEDICAL TECHNOLOGIES
12.2.8 COMPUMEDICS LIMITED
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key industry insights
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V.
FIGURE 8 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022)
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 11 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET
2.8 IMPACT OF RECESSION ON RESPIRATORY DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION)
FIGURE 14 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION)
FIGURE 15 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION)
FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
FIGURE 18 TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET
4.2 GEOGRAPHICAL GROWTH OPPORTUNITIES: RESPIRATORY DIAGNOSTICS MARKET
FIGURE 19 NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022
4.3 REGIONAL MIX: RESPIRATORY DIAGNOSTICS MARKET
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 DEVELOPED VS. EMERGING ECONOMIES: RESPIRATORY DIAGNOSTICS MARKET, 2023 VS. 2029 (USD MILLION)
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of respiratory diseases
5.2.1.1.1 Growth in global geriatric population
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION
5.2.1.1.2 Urbanization and growing pollution levels
FIGURE 24 PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY YEAR)
5.2.1.1.3 Rising prevalence of tobacco smoking
TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS
5.2.1.1.4 Changing lifestyle, obesity, and physical inactivity
5.2.1.2 Increasing rate of preterm births
TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020
FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020
5.2.1.3 Increasing outbreaks of infectious diseases affecting respiratory system
5.2.1.4 Growing population with sleep disorders
5.2.1.5 Rising R&D investments for technologically advanced medical devices
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement policies
5.2.2.2 Availability of low-cost products from local manufacturers
5.2.3 OPPORTUNITIES
5.2.3.1 Increased market growth in Asia Pacific and Latin America
5.2.3.2 Improving POC diagnostics
5.2.3.3 Increasing ill effects of untreated sleep apnea
TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA
5.2.4 CHALLENGES
5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases
5.3 INDUSTRY TRENDS
5.3.1 RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES
5.3.2 FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS
5.3.3 INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
5.5 TARIFF AND REGULATORY ANALYSIS
5.5.1 REGULATORY ANALYSIS
5.5.1.1 North America
5.5.1.1.1 US
TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT
TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.1.2 Canada
TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.2 Europe
TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.3 Asia Pacific
5.5.1.3.1 Japan
TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.3.2 China
TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5.1.3.3 India
5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.1 North America
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.2 Europe
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.3 Rest of the World
TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.6 ECOSYSTEM MARKET MAP
FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET
5.7 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Digitalization of diagnostic tests
5.8.2 ADJACENT TECHNOLOGIES
5.8.2.1 Rapid respiratory diagnostic kits
5.8.3 COMPLEMENTARY TECHNOLOGIES
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS
FIGURE 29 PATENT PUBLICATION TRENDS, 2013 2023
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013 NOVEMBER 2023)
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013 NOVEMBER 2023)
5.10 TRADE ANALYSIS
TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION)
5.11 CASE STUDY ANALYSIS
TABLE 15 MONITORING OF COPD PATIENTS AT HOME
TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES
TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS
5.12 PORTER S FIVE FORCES ANALYSIS
TABLE 18 PORTER S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY CONFERENCES & EVENTS
TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023 2024
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.14.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
5.15 PRICING ANALYSIS
TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD)
5.15.1 AVERAGE SELLING PRICE TREND, BY REGION
5.16 ADJACENT MARKETS
FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET
5.17 UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES
5.18 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
5.18.1 USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE
5.19 REIMBURSEMENT SCENARIO ANALYSIS
TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET
6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE
6.1 INTRODUCTION
TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
6.2 INSTRUMENTS AND DEVICES
6.2.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET
TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021 2029 (USD MILLION)
6.3 ASSAYS AND REAGENTS
6.3.1 RISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET
TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021 2029 (USD MILLION)
6.4 SERVICES AND SOFTWARE
6.4.1 INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET
TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021 2029 (USD MILLION)
7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE
7.1 INTRODUCTION
TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
7.2 MECHANICAL TESTS
TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.2.1 PULMONARY FUNCTION TESTS
TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
7.2.2 SPIROMETRY
7.2.2.1 Spirometry to dominate pulmonary function tests segment during forecast period
TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.2.3 PEAK FLOW TESTS
7.2.3.1 Precise measurements from peak flow tests to help focus on effective treatment plans
TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.2.4 OBSTRUCTIVE SLEEP APNEA TESTS
7.2.4.1 Increased focus on diagnosis of sleep apnea at early stages to drive segment
TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.2.5 OTHER MECHANICAL TESTS
TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3 IMAGING TESTS
TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.3.1 X-RAY
7.3.1.1 Increased investments in advanced radiographic technologies for superior lung imaging to drive segment
TABLE 40 X-RAY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.2 COMPUTED TOMOGRAPHY
7.3.2.1 Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive segment
TABLE 41 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.3 MAGNETIC RESONANCE IMAGING
7.3.3.1 Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment
TABLE 42 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.4 POSITRON EMISSION TOMOGRAPHY
7.3.4.1 Increased focus on effective treatment and management of lung cancer to drive segment
TABLE 43 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.3.5 OTHER IMAGING TESTS
TABLE 44 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.4 TRADITIONAL DIAGNOSTIC TESTS
TABLE 45 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 46 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.4.1 IMMUNODIAGNOSTICS
7.4.1.1 Increased focus on rapid disease diagnosis to drive segment
TABLE 47 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.4.2 BIOCHEMICAL CHARACTERIZATION
7.4.2.1 Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment
TABLE 48 BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.4.3 MICROSCOPY
7.4.3.1 Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market
TABLE 49 MICROSCOPY MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5 MOLECULAR DIAGNOSTIC TESTS
TABLE 50 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 51 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
7.5.1 PCR
7.5.1.1 Development of portable, real-time PCR machines and assays to drive segment
TABLE 52 PCR MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.2 NUCLEIC ACID AMPLIFICATION
7.5.2.1 Growing focus on automated nucleic acid amplification processes to drive segment
TABLE 53 NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.3 IN SITU HYBRIDIZATION
7.5.3.1 Increased adoption of automated technologies for streamlined respiratory testing to drive segment
TABLE 54 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
7.5.4.1 Rising number of research activities on sequencing-based biomarkers to drive segment
TABLE 55 DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.5 MICROARRAYS
7.5.5.1 Easy and effective detection of genetic signatures across multiple genes to drive segment
TABLE 56 MICROARRAYS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS
TABLE 57 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION
8.1 INTRODUCTION
TABLE 58 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
8.2 TUBERCULOSIS
8.2.1 INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET
TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021 2029 (USD MILLION)
8.3 ASTHMA
8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021 2029 (USD MILLION)
8.4 LUNG CANCER
8.4.1 INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET
TABLE 61 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021 2029 (USD MILLION)
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
8.5.1 INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET
TABLE 62 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021 2029 (USD MILLION)
8.6 OTHER RESPIRATORY DISEASES
TABLE 63 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021 2029 (USD MILLION)
9 RESPIRATORY DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 64 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
TABLE 65 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021 2029 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET
TABLE 66 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021 2029 (USD MILLION)
9.4 OTHER END USERS
TABLE 67 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021 2029 (USD MILLION)
10 RESPIRATORY DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
FIGURE 35 RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT
TABLE 68 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021 2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 70 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 71 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 72 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 73 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 74 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 75 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 76 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 77 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 78 NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate North American respiratory diagnostics market during forecast period
TABLE 79 US: KEY MACROINDICATORS
TABLE 80 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 81 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 82 US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 83 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 84 US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 85 US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 86 US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 87 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 88 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market
TABLE 89 CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020)
TABLE 90 CANADA: KEY MACROINDICATORS
TABLE 91 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 92 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 93 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 94 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 95 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 96 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 97 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 98 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 99 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3 EUROPE
TABLE 100 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 101 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 102 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 103 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 104 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 105 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 106 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 107 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 108 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 109 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing public healthcare expenditure to drive market
TABLE 110 GERMANY: KEY MACROINDICATORS
TABLE 111 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 112 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 113 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 114 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 115 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 116 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 117 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 118 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 119 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing prevalence of COPD and growing geriatric population to drive market
TABLE 120 FRANCE: KEY MACROINDICATORS
TABLE 121 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 122 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 123 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 124 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 125 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 126 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 127 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 128 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 129 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.4 UK
10.3.4.1 Rising number of hospitals and increasing government funding to drive market
TABLE 130 UK: KEY MACROINDICATORS
TABLE 131 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 132 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 133 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 134 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 135 UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 136 UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 137 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 138 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 139 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Unfavorable reforms and reduction in healthcare expenditure by government to limit market
TABLE 140 ITALY: KEY MACROINDICATORS
TABLE 141 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 142 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 143 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 144 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 145 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 146 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 147 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 148 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 149 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Increasing healthcare spending and growing demand for home care services to drive market
TABLE 150 SPAIN: KEY MACROINDICATORS
TABLE 151 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 152 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 153 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 154 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 155 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 156 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 157 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 158 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 159 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 160 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 161 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 162 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 163 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 164 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 165 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 166 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 167 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 168 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 37 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
TABLE 169 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 170 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 171 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 172 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 174 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 177 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 178 ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market
TABLE 179 JAPAN: KEY MACROINDICATORS
TABLE 180 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 181 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 182 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 183 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 184 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 185 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 186 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 187 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 188 JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Modern healthcare systems and improved reimbursement policies to drive market
TABLE 189 CHINA: KEY MACROINDICATORS
TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Large patient population and availability of skilled medical professionals to drive market
TABLE 199 INDIA: KEY MACROINDICATORS
TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Growing prevalence of chronic lung diseases to drive market
TABLE 209 AUSTRALIA: KEY MACROINDICATORS
TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Increasing geriatric population and rising disposable income to drive market 220" "TABLE 219 SOUTH KOREA: KEY MACROINDICATORS
TABLE 220 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 221 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 222 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 223 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 224 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 225 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 226 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 227 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 228 SOUTH KOREA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 229 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 230 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 231 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 232 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5 LATIN AMERICA
TABLE 238 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021 2029 (USD MILLION)
TABLE 239 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 240 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 241 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 242 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 243 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 244 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 245 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 246 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 247 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Favorable healthcare initiatives by government to drive market
TABLE 248 BRAZIL: KEY MACROINDICATORS
TABLE 249 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 250 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 251 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 252 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 253 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 254 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 255 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 256 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 257 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Rising obesity rates and improving medical tourism to drive market
TABLE 258 MEXICO: KEY MACROINDICATORS
TABLE 259 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 260 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 261 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 262 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 263 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 264 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 265 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 266 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 267 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 268 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PATIENT POPULATION AND INCREASING PENETRATION OF PRIVATE HEALTH INSURANCE COMPANIES TO DRIVE MARKET
TABLE 277 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021 2029 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021 2029 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021 2029 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021 2029 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021 2029 (USD MILLION)
TABLE 285 MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021 2029 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY STRATEGIES/RIGHT TO WIN
TABLE 286 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET
11.3 REVENUE SHARE ANALYSIS
FIGURE 38 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2018 2022 (USD MILLION)
FIGURE 39 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2018 2022 (USD MILLION)
11.4 MARKET SHARE ANALYSIS
FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET SHARE FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2022
FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2022
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 42 COMPANY EVALUATION MATRIX, 2022
11.5.5 COMPANY FOOTPRINT
TABLE 287 PRODUCT AND SERVICE FOOTPRINT
TABLE 288 TEST TYPE FOOTPRINT
TABLE 289 END USER FOOTPRINT
TABLE 290 REGIONAL FOOTPRINT
TABLE 291 OVERALL COMPANY FOOTPRINT
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 43 START-UP/SME EVALUATION MATRIX, 2022
11.6.5 COMPETITIVE BENCHMARKING
11.7 COMPETITIVE SCENARIOS AND TRENDS
11.7.1 KEY PRODUCT LAUNCHES
TABLE 292 KEY PRODUCT LAUNCHES, 2021 2023
11.7.2 KEY DEALS
TABLE 293 KEY DEALS, 2021 2023
11.7.3 OTHER KEY DEVELOPMENTS
TABLE 294 OTHER KEY DEVELOPMENTS, 2021 2023
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 KONINKLIJKE PHILIPS N.V.
TABLE 295 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
12.1.2 BECTON, DICKINSON AND COMPANY
TABLE 296 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.3 ABBOTT
TABLE 297 ABBOTT: COMPANY OVERVIEW
FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2022)
12.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 298 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
12.1.5 GE HEALTHCARE
TABLE 299 GE HEALTHCARE: COMPANY OVERVIEW
FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
12.1.6 BIO-RAD LABORATORIES, INC.
TABLE 300 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
12.1.7 BIOMERIEUX
TABLE 301 BIOMERIEUX: COMPANY OVERVIEW
FIGURE 50 BIOMERIEUX: COMPANY SNAPSHOT (2022)
12.1.8 REVVITY, INC.
TABLE 302 REVVITY, INC.: COMPANY OVERVIEW
FIGURE 51 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
12.1.9 SEEGENE INC.
TABLE 303 SEEGENE INC.: COMPANY OVERVIEW
FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2022)
12.1.10 NIHON KOHDEN CORPORATION
TABLE 304 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2022)
12.1.11 VITALOGRAPH
TABLE 305 VITALOGRAPH: COMPANY OVERVIEW
12.1.12 SDI DIAGNOSTICS
TABLE 306 SDI DIAGNOSTICS: COMPANY OVERVIEW
12.1.13 RESMED
TABLE 307 RESMED: COMPANY OVERVIEW
FIGURE 54 RESMED: COMPANY SNAPSHOT (2022)
12.1.14 SIEMENS HEALTHCARE GMBH
TABLE 308 SIEMENS HEALTHCARE GMBH: COMPANY OVERVIEW
FIGURE 55 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022)
12.1.15 COSMED SRL
TABLE 309 COSMED SRL: COMPANY OVERVIEW
12.1.16 HOLOGIC, INC.
TABLE 310 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
12.1.17 QIAGEN
TABLE 311 QIAGEN: COMPANY OVERVIEW
FIGURE 57 QIAGEN: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 VYAIRE MEDICAL, INC.
12.2.2 VISBY MEDICAL, INC.
12.2.3 BRIOTA TECHNOLOGIES PVT. LTD.
12.2.4 BIRD HEALTHCARE
12.2.5 LOWENSTEIN MEDICAL TECHNOLOGY GMBH
12.2.6 PROAXSIS
12.2.7 NDD MEDICAL TECHNOLOGIES
12.2.8 COMPUMEDICS LIMITED
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
